Bacterial Conjunctivitis - Pipeline Review, H2 2011

Global Markets Direct, December 2011, Pages: 34

Bacterial Conjunctivitis – Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Bacterial Conjunctivitis - Pipeline Review, H2 2011', provides an overview of the Bacterial Conjunctivitis therapeutic pipeline. This report provides information on the therapeutic development for Bacterial Conjunctivitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bacterial Conjunctivitis. 'Bacterial Conjunctivitis - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Bacterial Conjunctivitis.
- A review of the Bacterial Conjunctivitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Bacterial Conjunctivitis pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Bacterial Conjunctivitis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Bacterial Conjunctivitis pipeline depth and focus of Bacterial Conjunctivitis therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Bacterial Conjunctivitis Therapeutic Products under Development, Key Players in Bacterial Conjunctivitis Therapeutics, Bacterial Conjunctivitis Pipeline Overview, Bacterial Conjunctivitis Pipeline, Bacterial Conjunctivitis Pipeline Assessment

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Bacterial Conjunctivitis Overview
Therapeutics Development
An Overview of Pipeline Products for Bacterial Conjunctivitis
Bacterial Conjunctivitis Therapeutics under Development by Companies
Mid Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Bacterial Conjunctivitis Therapeutics – Products under Development by Companies
Companies Involved in Bacterial Conjunctivitis Therapeutics Development
Alcon, Inc.
InSite Vision Incorporated
NovaBay Pharmaceuticals, Inc.
Bacterial Conjunctivitis – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AzaSite Xtra - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NVC-422 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AL-15469A + AL-6515 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NVC-727 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NVC-638 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NVC-704 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bacterial Conjunctivitis Therapeutics – Drug Profile Updates
Bacterial Conjunctivitis – Product Development Milestones
Bacterial Conjunctivitis – Product Development Milestones
Featured News & Press Releases
Dec 17, 2009: NovaBay To Receive Increase In Funding And Support From Alcon
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Bacterial Conjunctivitis, H2 2011
Products under Development for Bacterial Conjunctivitis – Comparative Analysis, H2 2011
Number of Products under Development by Companies, H2 2011
Comparative Analysis by Mid Clinical Stage Development, H2 2011
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2011
Products under Development by Companies, H2 2011
Alcon, Inc., H2 2011
InSite Vision Incorporated, H2 2011
NovaBay Pharmaceuticals, Inc., H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Bacterial Conjunctivitis Therapeutics – Drug Profile Updates

List of Figures
Number of Products under Development for Bacterial Conjunctivitis, H2 2011
Products under Development for Bacterial Conjunctivitis – Comparative Analysis, H2 2011
Products under Development by Companies, H2 2011
Mid Clinical Stage Products, H2 2011
Discovery and Pre-Clinical Stage Products, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products, H2 2011
Assessment by Route of Administration, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Assessment by Stage and Molecule Type, H2 2011

Customers who bought this item also bought

• Global Allergic Conjunctivitis Drug Pipeline Capsule - 2012
• Hospital Acquired Bacterial Infections Market to 2017 - Niche Players are Most Active in R&D, Positioning Them as Potential Acquisition Targets for Big Pharma
• Community-Acquired Infections – Pipeline Review, H1 2013
• Fungal Infections – Pipeline Review, H1 2013
• Nausea – Pipeline Review, H1 2013
• Drug Addiction – Pipeline Review, H1 2013
• Community-Acquired Bacterial Pneumonia (Event Driven)
• Community-Acquired Bacterial Pneumonia
• Pandemic Influenza – Pipeline Review, H1 2013
• Conjunctivitis Therapy Area Pipeline Report